Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Related Posts
China and U.S. trade officials to hold talks in London
U.S. President Donald Trump’s top trade officials are meeting with their Chinese counterparts in London on Monday for talks.
Trump’s pivot on tariffs shows that Wall Street still has a seat at his table
This past week shows that financial markets, and by proxy Wall Street statesmen like Jamie Dimon, are still guardrails on the Trump administration.
AI startups raised $104 billion in first half of year, but exits tell a different story
AI accounted for nearly two-thirds of all fundraising deal value in the first half of 2025, with the bulk of those dollars concentrated in a […]